Related Experiment Video
Updated: Sep 13, 2025
Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology
Published on: March 24, 2015
Detection of Somatostatin Receptors by Ligand Derivative Staining in Breast Tumors
Kento Iida1, Erina Iwabuchi2, Yasuhiro Miki3
1Department of Anatomic Pathology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Background/Aim:
Somatostatin receptors (SSTRs) are G protein-coupled receptors that inhibit tumor cell proliferation. SSTRs are also expressed in breast cancer cells, and examination of clinical breast cancer specimens has revealed that SSTRs are more prevalent in patients with lower malignancy rates. However, in clinical trials of breast cancer, no significant differences in survival rates were detected upon administration of somatostatin analogs, highlighting the importance of detecting SSTRs in tumor tissues. Herein, we determined the expression of SSTRs in breast tumors using immunohistochemistry and ligand derivative staining (LDS) and examined the relevance of SSTR expression.
Patients And Methods:
Pathological tissues from breast tumors diagnosed as invasive ductal carcinomas (n=85) or breast neuroendocrine tumors (NETs) (n=20) were used. Immunohistochemistry and LDS using fluorescein isothiocyanate (FITC)-labeled octreotide were performed to detect SSTR expression.
Results:
Immunohistochemistry of SSTR2 in breast cancer tissues revealed a significant positive association with estrogen receptor (ER) (p<0.001) status, a significant negative association with stage (p=0.023), and a negative association with pN (p=0.055), which did not reach statistical significance. LDS in breast cancer demonstrated a significant positive association (p=0.027) with SSTR2 immunohistochemistry, a positive tendency with ER (p=0.065), and a negative association with pN (p=0.061). LDS in breast NETs was not associated with SSTR2 expression.
Conclusion:
Our findings revealed that immunohistochemistry allows specific detection of SSTR isoforms, whereas LDS could comprehensively evaluate SSTR expression. To the best of our knowledge, this is the first study to detect SSTR expression in breast cancer tissues using LDS, and the results suggest LDS as a new mode of evaluating SSTR status in clinical specimens.
Insights
This study shows ligand derivative staining (LDS) can effectively detect somatostatin receptors (SSTRs) in breast tumors, offering a new method for evaluating SSTR status in clinical settings.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Somatostatin receptors (SSTRs) are G protein-coupled receptors crucial for inhibiting tumor cell proliferation.
- SSTRs are present in breast cancer cells, with higher prevalence linked to lower malignancy rates.
- Previous clinical trials showed no survival benefit from somatostatin analogs, emphasizing the need for accurate SSTR detection in tumors.
Purpose of the Study:
- To determine somatostatin receptor (SSTR) expression in breast tumors using immunohistochemistry and ligand derivative staining (LDS).
- To examine the clinical relevance of SSTR expression in breast cancer and neuroendocrine tumors (NETs).
Main Methods:
- Analyzed pathological tissues from 85 invasive ductal carcinomas and 20 breast NETs.
- Employed immunohistochemistry and LDS with fluorescein isothiocyanate (FITC)-labeled octreotide to detect SSTR expression.
Main Results:
- Immunohistochemistry showed SSTR2 positively associated with estrogen receptor (ER) status and negatively with tumor stage in breast cancer.
- LDS in breast cancer correlated positively with SSTR2 immunohistochemistry and showed a tendency with ER status.
- LDS in breast NETs did not show association with SSTR2 expression.
Conclusions:
- Immunohistochemistry specifically detects SSTR isoforms, while LDS comprehensively evaluates overall SSTR expression.
- LDS represents a novel method for assessing SSTR status in clinical breast cancer specimens.
- This study is the first to utilize LDS for detecting SSTR expression in breast cancer tissues.
